Back to list

Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: Results from the A1chieve observational study

Siddharth Shah, Alexey Zilov, Rachid Malek, Pradana Soewondo, Ole Bech and Leon Litwak

Diabetes Research and Clinical Practice, Issue 3, Volume 94, pages 364 - 370

Received 20 September 2011, Revised 10 October 2011, Accepted 13 October 2011, Published online Nov-2011


Article view:

Authors

Siddharth Shah a lowast , Alexey Zilov b, Rachid Malek c, Pradana Soewondo d, Ole Bech e and Leon Litwak f

Footnotes

a Bhatia Hospital, Bombay Mutual Terrace, 534 Sandhurst Bridge, 3rd Floor, Mumbai 400007, India

b Department of Endocrinology, First Moscow State Medical University, 1 Pogodinskaya Street, Office 622, Moscow, Russia

c Internal Medicine, CHU Sétif, Sétif 19000, Algeria

d Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Jalan Diponegoro No. 71, Jakarta 10430, Indonesia

e Novo Nordisk Pharmaceuticals, 18F, East Tower, World Financial Center, No. 1, East 3rd Ring Middle Road, Caoyang District, Beijing 100020, China

f Endocrinology and Nuclear Medicine: Diabetes and Metabolism Section, Hospital Italiano de Buenos Aires, Lafinur 3050 Piso 8° Dpto. 2, (1425) Ciudad De Buenos Aires, Argentina

lowast Corresponding author. Tel.: +91 22 2361 2146; fax: +91 22 6666 0566.

Grant support: The A1chieve study was funded by Novo Nordisk.

☆☆ Clinical trial registration: Clinicaltrials.gov, NCT00869908.


Back to list